USANA Health Sciences (NYSE:USNA) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS

USANA Health Sciences (NYSE:USNA) issued its quarterly earnings data on Tuesday. The company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.22, RTT News reports. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $256.22 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The company’s revenue was down 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.24 earnings per share. USANA Health Sciences updated its FY 2019 guidance to $3.90-4.05 EPS and its FY19 guidance to $3.90-4.05 EPS.

NYSE:USNA traded up $2.72 during mid-day trading on Tuesday, reaching $72.62. 151,573 shares of the company’s stock were exchanged, compared to its average volume of 246,984. USANA Health Sciences has a one year low of $58.30 and a one year high of $125.61. The firm has a market capitalization of $1.55 billion, a PE ratio of 14.07 and a beta of 0.39. The business’s fifty day simple moving average is $69.55 and its two-hundred day simple moving average is $72.32.

In related news, Director Robert Auciaux sold 4,018 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. 42.50% of the stock is currently owned by company insiders.

Several brokerages have recently weighed in on USNA. TheStreet lowered shares of USANA Health Sciences from a “b-” rating to a “c+” rating in a research report on Thursday, July 11th. ValuEngine raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Pivotal Research reaffirmed a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on shares of USANA Health Sciences in a research report on Thursday, August 22nd. They set a “hold” rating and a $65.00 price target on the stock. Finally, Sidoti lowered shares of USANA Health Sciences from a “buy” rating to a “neutral” rating and set a $70.00 price target on the stock. in a research report on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. USANA Health Sciences currently has an average rating of “Hold” and a consensus price target of $70.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: Why is the price-sales ratio important?

Earnings History for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.